Skip to main content
Erschienen in: Strahlentherapie und Onkologie 2/2018

16.11.2017 | Original Article

Radiotherapy for extramedullary leukaemic manifestation (Chloroma)

verfasst von: Michael Oertel, MD, Khaled Elsayad, MD, Prof. Uwe Haverkamp, PhD, Prof. Matthias Stelljes, MD, Prof. Hans Theodor Eich, MD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Extramedullary leukaemic disease (EMD, synonym chloroma) is a rare solid manifestation of myeloid leukaemia for which the value of radiotherapy (RT) as a treatment strategy remains controversial. The aim of this study is to analyse the effectiveness of various RT doses for EMD in the modern treatment era.

Materials and methods

Between January 2000 and June 2016, 20 patients with total of 45 lesions underwent RT for EMD at our institution.

Results

With a median radiation dose of 26 Gy (range 4–42 Gy), local remission could be achieved in 91% of patients (complete remission rate: 71%). The median duration of local control (DOLC) was 17 months (95% confidence interval [CI] 0.5–33) and the median overall survival (OS) after chloroma onset was 24 months (95% CI 11–38). No noticeable difference between high- and low-dose regimens has been observed (74% versus 68%; P = 0.5). In the multivariate analysis, only Eastern Cooperative Oncology Group (ECOG) score and bone marrow state during RT have proven to be determinant for durable local control and OS.

Conclusions

Low-dose RT (≤26 Gy) achieves good local control compared to high-dose regimes. Bone marrow state during RT and ECOG score during RT may play a crucial role, influencing both DOLC and OS.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
5.
Zurück zum Zitat King A (1853) A case of chloroma. Monthly J Med 17:97 King A (1853) A case of chloroma. Monthly J Med 17:97
7.
Zurück zum Zitat Chak LY, Sapozink MD, Cox RS (1983) Extramedullary lesions in non-lymphocytic leukemia: results of radiation therapy. Int J Radiat Oncol Biol Phys 9:1173–1176CrossRefPubMed Chak LY, Sapozink MD, Cox RS (1983) Extramedullary lesions in non-lymphocytic leukemia: results of radiation therapy. Int J Radiat Oncol Biol Phys 9:1173–1176CrossRefPubMed
9.
Zurück zum Zitat Meis JM, Butler JJ, Osborne BM, Manning JT (1986) Granulocytic sarcoma in nonleukemic patients. Cancer 58:2697–2709CrossRefPubMed Meis JM, Butler JJ, Osborne BM, Manning JT (1986) Granulocytic sarcoma in nonleukemic patients. Cancer 58:2697–2709CrossRefPubMed
21.
Zurück zum Zitat Collis SJ, Neutzel S, Thompson TL et al (2004) Hematopoietic progenitor stem cell homing in mice lethally irradiated with ionizing radiation at differing dose rates. Radiat Res 162:48–55CrossRefPubMed Collis SJ, Neutzel S, Thompson TL et al (2004) Hematopoietic progenitor stem cell homing in mice lethally irradiated with ionizing radiation at differing dose rates. Radiat Res 162:48–55CrossRefPubMed
23.
Zurück zum Zitat Sauer MG (2015) Cognitive deficits following hematopoietic stem cell transplantation in childhood. Strahlenther Onkol 191:456–457CrossRefPubMed Sauer MG (2015) Cognitive deficits following hematopoietic stem cell transplantation in childhood. Strahlenther Onkol 191:456–457CrossRefPubMed
28.
Zurück zum Zitat Port M, Böttcher M, Thol F et al (2014) Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis. Ann Hematol 93:1279–1286. https://doi.org/10.1007/s00277-014-2072-6 CrossRefPubMed Port M, Böttcher M, Thol F et al (2014) Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis. Ann Hematol 93:1279–1286. https://​doi.​org/​10.​1007/​s00277-014-2072-6 CrossRefPubMed
29.
Zurück zum Zitat Carow CE, Levenstein M, Kaufmann SH et al (1996) Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood 87:1089–1096PubMed Carow CE, Levenstein M, Kaufmann SH et al (1996) Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood 87:1089–1096PubMed
30.
Zurück zum Zitat Rosnet O, Bühring HJ, Marchetto S et al (1996) Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 10:238–248PubMed Rosnet O, Bühring HJ, Marchetto S et al (1996) Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 10:238–248PubMed
36.
Metadaten
Titel
Radiotherapy for extramedullary leukaemic manifestation (Chloroma)
verfasst von
Michael Oertel, MD
Khaled Elsayad, MD
Prof. Uwe Haverkamp, PhD
Prof. Matthias Stelljes, MD
Prof. Hans Theodor Eich, MD
Publikationsdatum
16.11.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 2/2018
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-017-1236-4

Weitere Artikel der Ausgabe 2/2018

Strahlentherapie und Onkologie 2/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.